OBJECTIVES: To present a rationale and a proposed structure to support pharmacist-delivered medication therapy management (MTM) for human immunodeficiency virus (HIV ) disease and to outline challenges to implementing and sustaining the service. DATA SOURCES: Professional literature. SUMMARY: Historically, the effect of pharmacy services for HIV-infected persons has been demonstrated in inpatient and clinic-based settings. Developing similar programs adapted for community pharmacists could be a model of care to improve patient adherence to antiretroviral therapy and retention in care. Initiation of antiretroviral therapy and regular monitoring of CD4+ cell count, HIV RNA viral load, adverse drug events, and adherence form the backbone of successful medical management of HIV infection. Support for these services can be provided to HIV-infected patients through pharmacist-managed HIV MTM programs in community pharmacy settings in collaboration with primary providers and other health care professionals. CONCLUSION: Community pharmacists can help meet the growing need for HIV care through provision of MTM services. Although resources have been developed, including the general MTM framework, challenges of adequate training, education, and support of community pharmacists need to be addressed in order for HIV MTM to be a successful model.
OBJECTIVES: To present a rationale and a proposed structure to support pharmacist-delivered medication therapy management (MTM) for human immunodeficiency virus (HIV ) disease and to outline challenges to implementing and sustaining the service. DATA SOURCES: Professional literature. SUMMARY: Historically, the effect of pharmacy services for HIV-infectedpersons has been demonstrated in inpatient and clinic-based settings. Developing similar programs adapted for community pharmacists could be a model of care to improve patient adherence to antiretroviral therapy and retention in care. Initiation of antiretroviral therapy and regular monitoring of CD4+ cell count, HIV RNA viral load, adverse drug events, and adherence form the backbone of successful medical management of HIV infection. Support for these services can be provided to HIV-infectedpatients through pharmacist-managed HIV MTM programs in community pharmacy settings in collaboration with primary providers and other health care professionals. CONCLUSION: Community pharmacists can help meet the growing need for HIV care through provision of MTM services. Although resources have been developed, including the general MTM framework, challenges of adequate training, education, and support of community pharmacists need to be addressed in order for HIV MTM to be a successful model.
Authors: Stuart J Beatty; Kelly M McCormick; David J Beale; Athena M Bruggeman; Jennifer L Rodis; Bella H Mehta; Marialice S Bennett Journal: J Am Pharm Assoc (2003) Date: 2012 Mar-Apr
Authors: Michael A Horberg; Leo B Hurley; William J Towner; Michael W Allerton; Beth T Tang; Sheryl L Catz; Michael J Silverberg; Charles P Quesenberry Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Joel E Gallant; Adaora A Adimora; J Kevin Carmichael; Michael Horberg; Mari Kitahata; E Byrd Quinlivan; James L Raper; Peter Selwyn; Steven Bruce Williams Journal: Clin Infect Dis Date: 2011-10-20 Impact factor: 9.079
Authors: Elizabeth A Chrischilles; Barry L Carter; Brian C Lund; Linda M Rubenstein; Shari S Chen-Hardee; Margaret D Voelker; Tae-Ryong Park; Angela K Kuehl Journal: J Am Pharm Assoc (2003) Date: 2004 May-Jun
Authors: Patricia Murphy; Jennifer Cocohoba; Andrew Tang; Glen Pietrandoni; John Hou; B Joseph Guglielmo Journal: AIDS Patient Care STDS Date: 2012-08-03 Impact factor: 5.078
Authors: Jennifer Kibicho; Steven D Pinkerton; Jill Owczarzak; Lucy Mkandawire-Valhmu; Peninnah M Kako Journal: J Am Pharm Assoc (2003) Date: 2015 Jan-Feb
Authors: Carol Holtzman; Carl Armon; Ellen Tedaldi; Joan S Chmiel; Kate Buchacz; Kathleen Wood; John T Brooks Journal: J Gen Intern Med Date: 2013-04-20 Impact factor: 5.128
Authors: M E Molas; H Knobel; O Ferrández; M de Antonio Cuscó; N Carballo Martínez; C Rodríguez Caba; S Luque; A Guelar; S Castañeda Espinosa; S Grau Journal: Rev Esp Quimioter Date: 2021-11-26 Impact factor: 1.553